

Appl. No. 09/934,634  
Amdt. Dated October 28, 2003  
Reply to Office action of August 8, 2003

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-18 (deleted).

Claim 19 (new): A method of preventing, inhibiting or reducing fetal loss comprising administering an effective amount of an OX-2 protein to an animal in need thereof, wherein said OX-2 protein is capable of preventing, inhibiting or reducing fetal loss.

Claim 20 (new): A method according to claim 19 wherein the OX-2 protein comprises the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:19 or SEQ ID NO:21.

Claim 21 (new): A method according to claim 19 wherein said OX-2 protein can inhibit an in vitro immune response selected from the group consisting of: inhibiting a mixed leukocyte reaction; inhibiting a cytotoxic T lymphocyte response; inhibiting interleukin-2 production; and inhibiting interferon- $\gamma$  production.

Claim 22 (new): A method according to claim 19 wherein the OX-2 protein is a soluble fusion protein.

Claim 23 (new): A method according to claim 22 wherein the soluble fusion protein comprises an OX-2 protein linked to an immunoglobulin Fc region.

Claim 24 (new): A method according to claim 19 wherein the OX-2 protein is from a human OX-2 protein.

Appl. No. 09/934,634  
Amdt. Dated October 28, 2003  
Reply to Office action of August 8, 2003

Claim 25 (new): A method of preventing, inhibiting or reducing fetal loss comprising administering an effective amount of a fragment of an OX-2 protein to an animal in need thereof, wherein said OX-2 protein fragment is capable of suppressing an immune response selected from the group consisting of: inhibiting a mixed leukocyte reaction; inhibiting a cytotoxic T lymphocyte response; inhibiting interleukin-2 production; and inhibiting interferon- $\gamma$  production.

Claim 26 (new): A method according to claim 25 wherein the OX-2 protein fragment comprises a fragment of an amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:19 or SEQ ID NO:21.

Claim 27 (new): A method according to claim 25 wherein the OX-2 protein fragment is a soluble fusion protein.

Claim 28 (new): A method according to claim 27 wherein the soluble fusion protein comprises an OX-2 protein fragment linked to an immunoglobulin Fc region.

Claim 29 (new): A method according to claim 28 wherein the soluble fusion protein comprises OX-2 ED-Fc.

Claim 30 (new): A method according to claim 25 wherein the OX-2 protein fragment is from a human OX-2 protein.